Dr. Vipul Sheth

MBBS, MD (Medicine)

Sr. Consultant & Unit Head – Hemato Oncology & BMTU

Book an Appointment

About

Dr. Vipul Sheth is one of the leading Hemato-oncologist in India, with special interest in CAR t cells, T cells engineering/cellular therapy and bone marrow transplant. He is having more than 12 years of experience in the same field.

He is routinely involved in taking care of bone marrow transplants, cellular therapy for more than a decade. After completing his DM in medical oncology from the Tata Memorial hospital in Bombay he has worked as a senior physician in the field of stem cell transplant at the reputed Hadassah Ein Kerem in Israel for 2 years, which was the pioneering center in Europe to have started this comprehensive program. He was associated with Prof Arnon Nagler and Prof Reuven Or who are considered as founding members of Bone marrow transplant society in Europe. He has later on worked as a senior physician in the field of cellular therapy and CAR t cells for haematological malignancies at the Kings College hospital in London, UK for 2 years under the able guidance of Prof Ghulam Mufti who has been a pioneer and founding member in the field of MDS/leukemia and aplastic anaemia.

He further continued to work for 5 years in the field of Bone marrow transplant and lab services (post doc) at the world-renowned Fred Hutchinson Cancer center in Seattle USA/University Alabama Birmingham- where the first bone marrow transplant and cellular therapy was performed under the leadership of Nobel laureate Prof Sir Donal Thomas. He has worked in lab under the guidance of Dr Marie Bleakley and prof Ravi Bhatia-who is considered a giant in the field of chronic and acute leukemia- and was involved in development of clinical trials related to T cells therapy, biology of stem cells, genomics and metabolomics, and translational research in T cell biology and therapy. His expertise and lab interests are flow cytometry for MRD level disease in AML, genetic engineering, multi-omics and bioinformatics. He continues to be a visiting physician and collaborates with these centres actively. He is an invited member of prestigious societies like EBMT, and EHA and is associated with acute leukemia, chronic leukemia, severe aplastic anaemia and cellular therapy working party of EBMT. He has published more than 30 papers in prestigious international journals like Blood, leukemia, Blood cancer journal, Bone marrow transplant, and Blood advances. His seminal work in stem cell origin and metabolism has been published recently in blood and leukemia journals. He is an invited reviewer of international journals like BMT, BBMT, British journal haematology, Blood cancer journal. He has also completed diploma in clinical trials from the prestigious London school of tropical medicine and hygiene.

With his vast experience in this field (lab and clinical) he wants to develop and take this field further in India and has joined as a senior consultant and head of unit 3 in haematology.

Specialized Areas

Acute leukemia
Severe aplastic anaemia
Chronic leukemia
Bone marrow transplant- including half matched transplant (haploidentical donor transplants)
Cellular therapy and T cell engineering

Educational Background

B.B.S, Grant Medical College, Mumbai, India (2005)
Post-Graduate Training: 2005-2008 – MD Medicine
Residency, Internal Medicine, BYL Nair Hospital, Bombay, India (2008 – 2009)
Fellowship in training haematology, CMC Vellore, India / Tata Memorial Hospital, Mumbai, India 2010 – 2014
Fellowship (DM), Haemato-oncology Bone marrow transplant and solid tumours, Tata Memorial Hospital, Mumbai, India

Licensure, Certifications

2008 India- active, Israel (2015- inactive), UK- 2017 active
Board Certification or Eligibility (equivalent): 2014
Homi Bhabha institute of science, Mumbai, India
Diploma in clinical trials, London school of tropical hygiene
Board certification USMLE step1 and step 2- USA national board exams

Honours and Awards / Educational Grants and Scholarships

Berry foundation scholarship for a year of training in UK, for gold medal in internal medicine and academic distinction
Senior physician and member of EBMT working parties- ALWP, CMWP, SAA, CITWP

Experience

2014 – 2015: Clinical Instructor (Assistant Professor) – Prince Aly Khan Hospital, Mumbai, India
2017 – 2018: Assistant Professor Tata Memorial Hospital, Mumbai, India
2015 – 2019: Senior physician in Bone marrow transplant- Hadassah Ein Kerem, Jerusalem, Israel Senior physician in haematology (myeloid disorders/AA)/cellular therapy Kings College hospital, London, UK
2019-2024: Post doc fellowship/clinical attending- program in immunology- clinical research division- Fred Hutchinson Cancer Research center, USA
2024-Present : Sr. Consultant & Unit Head – Hemato Oncology & BMTU – Rajiv Gandhi Cancer Institute & Research Centre.

Professional Journey

Senior physician- Hadassah Ein Kerem, Israel- May 2015- March 2017. Member of Israel society of BMT- May 2017 till date
Fellowship (Royal college of physicians)/senior physician in BMT and cellular therapy/myeloid disorders- Kings College hospital, London- May 2017- October 2018
Consultant medical oncology and stem cell transplant – Tata Memorial hospital, Mumbai – June 2017- April 2018
Post-doc fellowship/senior physician- Fred Hutchinson Cancer research Center- 1/3/2019 till January 2024
Sr. Consultant & Unit Head – Hemato Oncology & BMTU – Rajiv Gandhi Cancer Institute and research centre – 8/1/2024 till date

Bibliography: Original Articles Published

Anderson NR, Sheth V, Li H, Harris MW, Qiu S, Crossman DK, et al. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling. Leukemia. 2023;37(3):560-70.
Sheth V, Qui S et al, Metabolic adaptation of leukemic stem cells to TKI- accepted for publication Blood- 2023
Raj K, Eikema DJ, Sheth V, Koster L, de Wreede LC, Blaise D, et al. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. Blood Cancer J. 2022;12(9):140.
Sheth V…. Mclornan D, Raj K, et al Pre-emptive DLI- Long term outcomes of patients with mixed chimerism in acute Leukaemia- Blood cancer journal- June 2021
Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy Bone Marrow Transplant. 2020.
Sheth V, Volt F, Sanz J, Clement L, Cornelissen J, Blaise D, et al. Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. Biol Blood Marrow Transplant. 2020;26(11):2098-104.
Biernacki MA, Sheth VS, Bleakley M. T cell optimization for graft-versus-leukemia responses. JCI Insight. 2020;5(9).
Summers C, Sheth VS, Bleakley M. Minor Histocompatibility Antigen-Specific T Cells. Front Pediatr. 2020; 8:284.
Sheth VS, Potter V, Gandhi SA, Kulasekararaj AG, de Lavallade H, Muus P, et al. Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. Blood Adv. 2019;3(20):3070-9.
Sheth V, Kennedy V, de Lavallade H, McLornan D, Potter V, Engelhardt BG, et al. Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience. Front Oncol. 2019; 9:623.
Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, et al. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone Marrow Transplant. 2019;54(4):531-9.
Sheth V, Nachmias B, Grisariu S, Avni B, Or R, Shapira M. Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia – improved outcomes with similar toxicity. Leuk Lymphoma. 2019;60(3):726-33.
Sheth V, Grisariu S, Avni B, Stepensky P, Ashkenazi M, Shapira MY, et al. Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation. Pediatr Blood Cancer. 2018;65(11): e27312.
Shapira MY, Klimov A, Vipul S, Grisariu S, Avni BR, Or R, et al. Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD. Bone Marrow Transplant. 2017;52(10):1416-22.
Sheth V, Gore A, Jain R, Ghanekar A, Saikia T. Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell Transplant. Indian J Hematol Blood Transfus. 2019;35(1):66-71.
Sheth V, Jain R, Gore A, Ghanekar A, Saikia T. Engraftment Syndrome: Clinical Features and Predictive Factors in Autologous Stem Cell Transplant. Indian J Hematol Blood Transfus. 2018;34(3):448-53.
Gulia S, Bajpai J, Gupta S, Maheshwari A, Deodhar K, Kerkar RA, Sheth V et al. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India. Clin Oncol (R Coll Radiol). 2014;26(1):39-44.
Sirohi B, Rastogi S, Singh A, Sheth V, Dawood S, Talole S, et al. Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer. Future Oncol. 2015;11(8):1191-200.
Sheth V, Jain R, Saikia T, et al.
Pre-emptive and Upfront Plerixafor: Safe and Effective Strategy for Patients Undergoing Autologous Stem Cell Transplant and at High Risk for Mobilization Failure. Indian Journal of Medical and Paediatric Oncology 2020
Sheth V, Raj K…. Mclornan D, Kroger N et al- Matched siblings compared to mismatched family donor transplantation for PMF: behalf of CMWP/EBMT accepted Blood cancer journal 2024